- Mixed Financials: Strong revenue growth, but earnings per share (EPS) fell short of analyst expectations.
- Revenue Beat: Total revenue of $240.34 million surpassed estimates, driven by BRIUMVI sales.
- Raised Outlook: The company increased its full-year 2026 total global revenue guidance to approximately $950 million.
TG Therapeutics (NASDAQ: TGTX) is a biopharmaceutical company that develops treatments for B-cell diseases. Its main product is BRIUMVI, a drug used to treat relapsing multiple sclerosis. The company’s recent earnings report on August 3, 2026, presented a mixed financial picture with strong sales but missed profit expectations.
On the earnings front, TG Therapeutics announced an earnings per share (EPS) of $0.05. This result fell short of the consensus analyst estimate of $0.31. As highlighted by Zacks, this represents an earnings surprise of -87.81% and is a decrease from the $0.17 per share reported a year ago.
In contrast to its earnings, the company’s revenue performance was strong. TG Therapeutics reported total revenue of $240.34 million for the period. This figure surpassed the estimated $229.77 million and shows significant growth from the $141.15 million reported in the same quarter of the previous year.
The impressive revenue is mainly driven by sales of BRIUMVI. The drug’s U.S. net product revenue was approximately $228 million, marking over 64% growth from the prior year. This growth is supported by a record number of new patients starting the treatment and expanding prescriber adoption.
Following these strong sales, TG Therapeutics raised its financial outlook for the full year 2026. The company now projects total global revenue of approximately $950 million. The guidance for U.S. BRIUMVI net revenue was also increased to a range between $890 million and $905 million.
